G protein-coupled receptor-35 (GPR35) has been shown to be a target of the asthma drugs cromolyn disodium and nedocromil sodium. Gallic acid and caffeic acids are reported to modulate allergic reactions via unknown mode(s) of action. Here we attempt to elucidate whether both phenolic acids share a common mode of action with the two asthma drugs. Label-free dynamic mass redistribution (DMR) assays showed that both phenolic acids triggered robust DMR signals in HT-29 cells, whose characteristics were similar to that of cromolyn disodium. Both phenolic acids resulted in detectable β-arrestin translocation signals in an engineered U2OS cell line stably expressing a C-terminal-modified GPR35, but with lower efficacy than cromolyn disodium. Antiallergic wedelolactone was found to be a potent β-arrestin-biased GPR35 agonist. These results suggest that certain anti-inflammatory phytochemicals including gallic acid and wedelolactone may modulate inflammatory allergic action via their agonism at GPR35. GPR35 may represent a target for the treatment of allergic disorders including asthma.

1.
MacKenzie AE, Lappin JE, Taylor DL, Nicklin SA, Milligan G: GPR35 as a novel therapeutic target. Front Endocrin 2011;2:e68.
2.
Taniguchi Y, Tonai-Kachi H, Shinjo K: Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35. FEBS Lett 2006;580:5003–5008.
3.
Wang J, Simonavicius N, Wu X, Swaminath G, Reagan J, Tian H, Ling L: Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem 2006;281:22021–22028.
4.
Lattin JE, Schroder K, Su AI, Walker JR, Zhang J, Wiltshire T, Saijo K, Glass CK, Hume DA, Kellie S, Sweet MJ: Expression analysis of G protein-coupled receptors in mouse macrophages. Immunome Res 2008;4:5.
5.
Sparfel L, Pinel-Marie ML, Boize M, Koscielny S, Desmots S, Pery A, Fardel O: Transcriptional signature of human macrophages exposed to the environmental contaminant benzo(a)pyrene. Toxicol Sci 2010;114:247–259.
6.
Yang Y, Lu JYL, Wu X, Summer S, Whoriskey J, Saris C, Reagan JD: G-protein-coupled receptor 35 is a target of the asthma drugs cromolyn disodium and nedocromil sodium. Pharmacology 2010;86:1–5.
7.
Fallarini S, Magliulo L, Paoletti T, de Lalla C, Lombardi G: Expression of functional GPR35 in human iNKT cells. Biochem Biophys Res Commun 2010;398:420–425.
8.
Barth MC, Ahluwalia N, Anderson TJ, Hardy GJ, Sinha S, Alvarez-Cardona JA, Pruitt IE, Rhee EP, Colvin RA, Gerszten RE: Kynurenic acid triggers firm arrest of leukocytes to vascular endothelium under flow conditions. J Biol Chem 2009;284:19189–19195.
9.
Newman DJ, Cragg GM: Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007;70:461–477.
10.
Kim SH, Jun CD, Suk K, Choi BJ, Lim H, Park S, Lee, SH, Shin HY, Kim DK, Shin TY: Gallic acid inhibits histamine release and pro-inflammatory cytokine production in mast cells. Toxicol Sci 200;91:123–131.
11.
Lee JY, Lee JG, Sim SS, Whang WK, Kim CJ: Anti-asthmatic effects of phenylpropanoid glycosides from Clerodendron trichotomum leaves and Rumex gmelini herbs in conscious guinea-pigs challenged with aerosolized ovalbumin. Phytomedicine 2011;18:134–142.
12.
Yang YF, Hsu JY, Fu LS, Weng YS, Chu JJ: Asthma drugs counter-regulate interlukin-8 release stimulated by sodium sulfite in an A549 cell line. J Asthma 2008;46:238–243.
13.
Rogerio AP, Fontanari C, Borducchi E, Keller AC, Russo M, Soares EG, Albuquerque DA, Faccioli LH: Anti-inflammatory effects of Lafoensia pacari and ellagic acid in a murine model of asthma. Eur J Pharmacol 2008;580:262–270.
14.
Rogerio AP, Sa-Nunes A, Faccioli LH: The activity of medicinal plants and secondary metabolites on eosinophilic inflammation. Pharmacol Res 2010;62:298–307.
15.
Chen S: Natural products triggering biological targets – a review of the anti-inflammatory phytochemicals targeting the arachidonic acid pathway in allergy asthma and rheumatoid arthritis. Curr Drug Targets 2011;12:288–301.
16.
Fang Y, Ferrie AM, Fontaine NH, Mauro J, Balakrishnan J: Resonant waveguide grating biosensor for living cell sensing. Biophys J 2006;91:1925–1940.
17.
Kenakin T: Cellular assays as portals to seven-transmembrane receptor-based drug discovery. Nat Rev Drug Discov 2009;8:617–626.
18.
Fang Y: The development of label-free cellular assays for drug discovery. Exp Opin Drug Discov 2011;6:1285–1298.
19.
Deng H, Hu H, Fang Y: Tyrphostin analogs are GPR35 agonists. FEBS Lett 2011;585:1957–1962.
20.
Deng H, Hu H, He M, Hu J, Niu W, Ferrie AM, Fang Y: Discovery of 2-(4-methylfuran-2(5H)-ylidene)malononitrile and thieno[3,2-b]thiophene-2-carboxylic acid derivatives as G protein-coupled receptor-35 (GPR35) agonists. J Med Chem 2011;54:7385–7396.
21.
Zhao P, Sharir H, Kapur A, Cowan A, Geller EB, Adler MW, Seltzman HH, Reggio PH, Heynen-Genel S, Sauer M, Chung TDY, Bai Y, Chen W, Caron MG, Barak LS, Abood ME: Targeting of the or-phan receptor GPR35 by pamoic acid: a potent activator of ERK and β-arrestin 2, with antino-ciceptive activity. Mol Pharmacol 2010;78:560–568.
22.
Deng H, Hu H, Ling S, Ferrie AM, Fang Y: Discovery of natural phenols as G protein-coupled receptor 35 (GPR35) agonists. ACS Med Chem Lett 2012;3:165–169.
23.
Barnes PJ: Drugs for asthma. Br J Pharmacol 2006;147:S297–S303.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.